Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

148Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Features of Parkinson's disease (PD) include oxidative stress, nigral mitochondrial complex I deficiency and visual dysfunction, all of which are also associated with coenzyme Q10 (CoQ10) deficiency. The objective of this monocenter, parallel group, placebo controlled, double-blind trial was to determine the symptomatic response of daily oral application of 360 mg CoQ10 lasting 4 weeks on scored PD symptoms and visual function, measured with the Farnsworth-Munsell 100 Hue test (FMT), in 28 treated and stable PD patients. CoQ10 supplementation provided a significant (P=0.01) mild symptomatic benefit on PD symptoms and a significantly (F(1,24)=8.48, P=0.008) better improvement of FMT performance compared with placebo. Our results indicate a moderate beneficial effect of oral CoQ10 supplementation in PD patients. © 2003 Elsevier Science Ireland Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Müller, T., Büttner, T., Gholipour, A. F., & Kuhn, W. (2003). Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neuroscience Letters, 341(3), 201–204. https://doi.org/10.1016/S0304-3940(03)00185-X

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free